Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343681 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8344661 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8343680 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL19873069 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| Octane SCHEMBL16439984 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL2179345 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL2179341 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL361243 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8344665 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL29709266 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | claimed |
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | TONG, Shuwen (CN) | 2025-10-16 | — | — | US | claimed |
| EP-4584278-A1 | 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY | Nutcracker Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025137277-A1 | DEGRADABLE PEPTOIDS | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | claimed |
| CN-119630637-A | Ionizable cationic lipids and lipid nanoparticles and methods of synthesis and use thereof | 潮汐疗法公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240307526-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | MEDICI THERAPEUTICS, INC. | 2024-09-19 | — | — | US | claimed |
| EP-4380949-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | Nutcracker Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2024054617-A1 | 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| CN-1166366-C | Process for producing composite preparation containing nucleic acid | �ձ���ҩ��ʽ���� | 2004-09-15 | — | — | CN | claimed |
| EP-0871758-B1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO KAI JOHANNES (FI) | 2004-03-31 | — | — | EP | claimed |
| CN-1303293-A | Process for producing composite preparation containing nucleic acid | NIPPON SHINYAKU CO LTD (JP) | 2001-07-11 | — | — | CN | claimed |
| CN-1294518-A | therapeutic agent for hepatitis | NIPPON SHINYAKU CO LTD (JP) | 2001-05-09 | — | — | CN | claimed |
| US-6074667-A | Liposomal transfection method | KINNUNEN PAAVO (FI) | 2000-06-13 | — | — | US | claimed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | claimed |
| EP-0871758-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN, Paavo Kai Johannes (FI) | 1998-10-21 | — | — | EP | claimed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | claimed |
| WO-1997019184-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO (FI) | 1997-05-29 | — | — | WO | claimed |
| US-5358714-A | Diacylglycerols as chemical activators of protein kinase C enzymes for inducing and increasing hair growth | UNILEVER PATENT HOLDINGS B.V. (NL) | 1994-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319035-A1 | CATIONIC LIPID NANOPARTICLE HAVING HIGH TRANSFECTION EFFICIENCY AND PREPARATION METHOD THEREFOR | CETP, NPC1L1, LIPA | FAAH 2098/4885CES1 78/4885DGKA 430/4885 |
| US-20240307526-A1 | COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS | TLR9, TLR3, MICA | FAAH 3571/4885CES1 3419/4885DGKA 1298/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | FAAH 1756/4885CES1 1402/4885DGKA 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.